What this test measures
CA 15-3 is a soluble fragment of MUC1, a mucin glycoprotein over-expressed on the surface of breast cancer cells and shed into the bloodstream. The test measures CA 15-3 in serum by immunoassay (typically chemiluminescence).
The marker is elevated in approximately 70–80% of patients with metastatic breast cancer, less commonly in early-stage disease. It can also rise modestly in benign breast conditions, chronic liver disease, lung disease, and other adenocarcinomas (ovary, lung, pancreas) — limiting its specificity.
Why it matters
CA 15-3 has a clear role in monitoring known breast cancer:
• Tracking response to chemotherapy or endocrine therapy in metastatic disease • Detecting recurrence in patients with prior breast cancer • Supporting clinical and imaging assessment of disease status
It is explicitly NOT recommended by ASCO, NCCN, or any major guideline as a screening test for breast cancer in asymptomatic women. False positives cause unnecessary anxiety, imaging, and biopsies; the test misses many early breast cancers (sensitivity ~10–20% in stage I disease). Mammography remains the standard screening tool.
For Indian women already diagnosed with breast cancer, CA 15-3 trends over time — taken together with clinical exam and imaging — help guide treatment decisions.
How to prepare
No fasting required. Standard venous blood sample. Mention any recent breast surgery or radiation, current treatment (chemotherapy, hormone therapy), and chronic conditions (liver disease, lung disease) that might raise CA 15-3 modestly. High-dose biotin supplements can interfere with some immunoassays — stop for 72 hours before sampling if possible.
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| CA 15-3 (U/mL)[1][2][3] | < 30 U/mL (lab-specific) | Low / normal CA 15-3 in a treated breast cancer patient is reassuring but does not exclude recurrence — combine with clinical exam and imaging. | Elevated CA 15-3 in a known breast cancer patient may indicate progression or recurrence. Modest elevation (30–100 U/mL) is also seen in cirrhosis, hepatitis, chronic lung disease, benign breast conditions and other adenocarcinomas. Very high values (> 100 U/mL) more often reflect metastatic breast cancer. |
When CA 15-3 is and is not appropriate
| Context | Use CA 15-3? | Notes |
|---|---|---|
| Screening asymptomatic women | No | Mammography is the standard |
| Initial breast cancer diagnosis | No | Imaging + biopsy are diagnostic |
| Monitoring metastatic breast cancer | Yes | Track response to therapy |
| Post-treatment recurrence surveillance | Selective | Used selectively per guideline |
| Early-stage disease post-curative therapy | Not routinely | Clinical exam + mammography preferred |
Frequently asked questions
Should I get a CA 15-3 test if I have a family history of breast cancer?
No. CA 15-3 is not a screening test. The right approach for women at increased risk (BRCA1/2 mutation, strong family history) is enhanced imaging surveillance — annual MRI plus mammography starting at an age set by your oncologist / genetic counsellor.
My CA 15-3 is mildly elevated — does that mean I have cancer?
Probably not. Mild elevations (30–60 U/mL) occur in many benign conditions: chronic liver disease, hepatitis, chronic lung disease, benign breast conditions, even pregnancy. In an asymptomatic woman with normal mammography, mild elevation is rarely cancer.
When is CA 15-3 actually useful?
When monitoring a confirmed breast cancer — tracking response to chemotherapy or endocrine therapy in metastatic disease, and supporting surveillance for recurrence.
How is CA 15-3 different from CA 27.29?
Both detect the same MUC1 antigen using slightly different antibodies. Performance is similar. Either can be used; the same marker should be tracked over time in a given patient.
Do I need to fast?
No.
How long does the report take?
Most NABL labs deliver CA 15-3 results in 24–48 hours.
Why do guidelines discourage routine CA 15-3 testing?
In early-stage breast cancer survivors, routine CA 15-3 monitoring does not improve survival but increases anxiety, false-positive workups, and cost. Clinical exam, mammography and symptoms-directed evaluation remain the standard. CA 15-3 is used selectively where it changes management.
Related Oncology / Tumor Markers tests
Tests commonly ordered alongside CA 15.3, or that help interpret an unexpected result.
Sources & references
- ASCO — Tumor Markers in Breast Cancer · accessed 2026-05-30T00:00:00.000Z
- NCCN — Breast Cancer Guidelines · accessed 2026-05-30T00:00:00.000Z
- American Cancer Society — Breast Cancer Tumor Markers · accessed 2026-05-30T00:00:00.000Z
- NCBI StatPearls — CA 15-3 · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your CA 15.3 test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book CA 15.3 now